Clinical Trials Using Glasdegib Maleate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Glasdegib Maleate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).
Location: 9 locations
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib / II trial studies the side effects and best dose of anti-OX40 antibody PF-04518600 (OX40) and how well it works alone or in combination with venetoclax, avelumab, glasdegib, gemtuzumab ozogamicin, and azacitidine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as OX40, avelumab, and gemtuzumab ozogamicin, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Glasdegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as venetoclax and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving OX40, venetoclax, avelumab, glasdegib, gemtuzumab ozogamicin, and azacitidine may work better in treating patients with acute myeloid leukemia.
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 and Glasdegib for the Treatment of Therapy-Related Acute Myeloid Leukemia
This phase II trial studies how well CPX-351 and glasdegib work for the treatment of therapy-related acute myeloid leukemia. CPX-351 is a combination of 2 chemotherapies, daunorubicin and cytarabine, and may work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Glasdegib is a smoothened inhibitor designed to reduce or stop the growth of leukemic cells. Giving CPX-351 and glasdegib together may slow the growth and spread of cancer in patients with therapy-related acute myeloid leukemia.
Location: 5 locations